aspirin has been researched along with Granulocytic Leukemia, Chronic in 9 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms, respectively characterized by erythrocytosis and thrombocytosis." | 2.52 | Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2015) |
| "Placental infarction due to thrombosis seems to be the most consistent event." | 2.40 | Fertility, pregnancy and the management of myeloproliferative disorders. ( Bergmann, L; Griesshammer, M; Pearson, T, 1998) |
| "Tyrosine kinase inhibitors (TKIs) used to treat chronic myeloid leukaemia (CML) can cause cardiovascular adverse events." | 1.72 | The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity. ( Alagna, G; Di Lisi, D; Madaudo, C; Novo, G; Rossetto, L; Santoro, M; Siragusa, S, 2022) |
| "Hypertension was reported in 14." | 1.51 | Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. ( Abruzzese, E; Albano, F; Annunziata, M; Attolico, I; Baratè, C; Binotto, G; Bonifacio, M; Breccia, M; Caocci, G; Castagnetti, F; Cattaneo, D; De Gregorio, F; Elena, C; Foà, R; Fozza, C; Galimberti, S; Gozzini, A; Gugliotta, G; Iurlo, A; La Nasa, G; Luciano, L; Mulas, O; Orlandi, EM; Pirillo, F; Pregno, P; Scaffidi, L; Scalzulli, E; Sgherza, N; Stagno, F; Trawinska, MM, 2019) |
| "Polycythemia Vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms respectively characterized by erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding, microcirculatory symptoms, pruritus, and risk of leukemic or fibrotic transformation." | 1.46 | Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. ( Barbui, T; Tefferi, A, 2017) |
| "The myeloproliferative disorders have been the "poor cousins" in the family of hematological malignancies for some time." | 1.33 | Platelets and thrombosis in myeloproliferative diseases. ( Harrison, CN, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Di Lisi, D | 1 |
| Madaudo, C | 1 |
| Alagna, G | 1 |
| Santoro, M | 1 |
| Rossetto, L | 1 |
| Siragusa, S | 1 |
| Novo, G | 1 |
| Usui, N | 1 |
| Caocci, G | 1 |
| Mulas, O | 1 |
| Abruzzese, E | 1 |
| Luciano, L | 1 |
| Iurlo, A | 1 |
| Attolico, I | 1 |
| Castagnetti, F | 1 |
| Galimberti, S | 1 |
| Sgherza, N | 1 |
| Bonifacio, M | 1 |
| Annunziata, M | 1 |
| Gozzini, A | 1 |
| Orlandi, EM | 1 |
| Stagno, F | 1 |
| Binotto, G | 1 |
| Pregno, P | 1 |
| Fozza, C | 1 |
| Trawinska, MM | 1 |
| De Gregorio, F | 1 |
| Cattaneo, D | 1 |
| Albano, F | 1 |
| Gugliotta, G | 1 |
| Baratè, C | 1 |
| Scaffidi, L | 1 |
| Elena, C | 1 |
| Pirillo, F | 1 |
| Scalzulli, E | 1 |
| La Nasa, G | 1 |
| Foà, R | 1 |
| Breccia, M | 1 |
| Tefferi, A | 2 |
| Barbui, T | 2 |
| Kälsch, H | 1 |
| Wieneke, H | 1 |
| Erbel, R | 1 |
| Harrison, CN | 1 |
| Wehmeier, A | 1 |
| Südhoff, T | 1 |
| Meierkord, F | 1 |
| Griesshammer, M | 1 |
| Bergmann, L | 1 |
| Pearson, T | 1 |
3 reviews available for aspirin and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Topics: Aspirin; Calreticulin; Diagnosis, Differential; Disease Management; Humans; Hydroxyurea; Janus Kinas | 2015 |
Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders.
Topics: Alkylating Agents; Arachidonic Acid; Aspirin; Bleeding Time; Blood Platelets; Bone Marrow; Hematopoi | 1997 |
Fertility, pregnancy and the management of myeloproliferative disorders.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Alkylating Agents; Animals; Aspirin; Bone Marrow | 1998 |
6 other studies available for aspirin and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity.
Topics: Adult; Aged; Aspirin; Cardiotoxicity; Chronic Disease; Female; Heart Failure; Humans; Inducible T-Ce | 2022 |
JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).
Topics: Algorithms; Aniline Compounds; Antineoplastic Agents; Aspirin; Blood Transfusion; Dasatinib; Hematop | 2017 |
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiology; Coronary Occlusion; Decision Support Systems, C | 2019 |
Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Topics: Aspirin; Calreticulin; Diagnosis, Differential; Erythropoietin; Humans; Hydroxyurea; Interferon-alph | 2017 |
Acute myocardial infarction in a patient with chronic myelocytic leukemia during chemotherapy with hydroxyurea.
Topics: Angioplasty, Balloon, Coronary; Anterior Wall Myocardial Infarction; Antineoplastic Agents; Aspirin; | 2010 |
Platelets and thrombosis in myeloproliferative diseases.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Endothelium, Vascular; Hematocrit; Humans; Janus | 2005 |